Xenetic Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Xenetic BiosciencesDer Gewinn des Unternehmens wird voraussichtlich um 34.4% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 35.9% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 25.8% pro Jahr wachsen.

Wichtige Informationen

-34.4%

Wachstumsrate der Gewinne

25.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	35.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Dec 15

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Dec 01

Xenetic Biosciences reports Q2 results

Aug 12

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Aug 02

Xenetic inks clinical manufacturing contract with Catalent

Jul 07

Xenetic Biosciences reports Q3 results

Nov 13

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:XBIO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2	-15	N/A	N/A	1
12/31/2025	2	-9	N/A	N/A	1
12/31/2024	2	-6	N/A	N/A	1
9/30/2024	3	-4	-3	-3	N/A
6/30/2024	3	-5	-3	-3	N/A
3/31/2024	2	-4	-4	-4	N/A
12/31/2023	3	-4	-4	-4	N/A
9/30/2023	2	-4	-4	-4	N/A
6/30/2023	2	-4	-4	-4	N/A
3/31/2023	2	-6	-4	-4	N/A
12/31/2022	2	-7	-5	-5	N/A
9/30/2022	2	-7	-6	-5	N/A
6/30/2022	1	-7	-6	-5	N/A
3/31/2022	1	-6	-5	-5	N/A
12/31/2021	1	-6	-5	-5	N/A
9/30/2021	1	-5	-4	-4	N/A
6/30/2021	1	-11	-4	-4	N/A
3/31/2021	1	-11	-5	-5	N/A
12/31/2020	0	-11	-4	-4	N/A
9/30/2020	0	-11	-5	-5	N/A
6/30/2020	0	-14	-6	-6	N/A
3/31/2020	0	-14	-6	-6	N/A
12/31/2019	0	-18	-6	-6	N/A
9/30/2019	N/A	-19	-6	-6	N/A
6/30/2019	N/A	-10	-5	-5	N/A
3/31/2019	N/A	-11	-6	-6	N/A
12/31/2018	N/A	-7	-6	-6	N/A
9/30/2018	8	-1	-1	-1	N/A
6/30/2018	8	-2	N/A	-1	N/A
3/31/2018	8	-3	N/A	0	N/A
12/31/2017	8	-4	N/A	1	N/A
9/30/2017	3	-12	N/A	-8	N/A
6/30/2017	3	-13	N/A	-7	N/A
3/31/2017	3	-58	N/A	-7	N/A
12/31/2016	3	-58	N/A	-9	N/A
9/30/2016	N/A	-57	N/A	-5	N/A
6/30/2016	N/A	-60	N/A	-6	N/A
3/31/2016	N/A	-14	N/A	-5	N/A
12/31/2015	N/A	-13	N/A	-5	N/A
9/30/2015	N/A	-13	N/A	-7	N/A
6/30/2015	N/A	-11	N/A	-8	N/A
3/31/2015	N/A	-13	N/A	-11	N/A
12/31/2014	N/A	-14	N/A	-13	N/A
9/30/2014	N/A	-14	N/A	-12	N/A
6/30/2014	N/A	-13	N/A	-12	N/A
3/31/2014	1	-11	N/A	-9	N/A
12/31/2013	1	-9	N/A	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: XBIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: XBIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: XBIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: XBIODie Einnahmen des Unternehmens (35.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: XBIODie Einnahmen des Unternehmens (35.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von XBIO in 3 Jahren voraussichtlich hoch sein wird

Xenetic Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased to US$4.00

Consensus forecasts updated

Consensus EPS estimates increase to -US$0.55

Price target increased to US$5.00

Recent updates

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting Potential of Co-Administration of DNase I with CAR T Cells in Murine Model of Melanoma Lung Metastasis

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Xenetic Biosciences, Inc. Announces the Presentation of Positive Preclinical Data

Xenetic Biosciences, Inc., Annual General Meeting, Dec 11, 2024

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Xenetic Biosciences, Inc. Announces the Appointment of James Parslow as Interim Chief Executive Officer

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CLS Therapeutics Discloses its Views on Xenetic Biosciences

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform

Xenetic Biosciences, Inc., Annual General Meeting, Dec 06, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Xenetic Biosciences, Inc., Annual General Meeting, Dec 21, 2022

Xenetic Biosciences Receives a Non-Compliance Letter from Nasdaq

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board

Price target increased to US$4.00

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xenetic Biosciences, Inc., Annual General Meeting, Dec 07, 2022

Xenetic Biosciences, Inc. announced that it expects to receive $0.488835 million in funding from CLS Therapeutics, Inc.

Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Xenetic Biosciences reports Q2 results

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Xenetic inks clinical manufacturing contract with Catalent

Xenetic Biosciences Receives Written Notification from the Listing Qualifications Department of the Nasdaq

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Xenetic Biosciences, Inc. announced that it has received $0.86625 million in funding

High number of new directors

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$1.20 loss in 3Q 2020)

Consensus EPS estimates increase to -US$0.55

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.15 loss in 2Q 2020)

Price target increased to US$5.00

Xenetic Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

Xenetic Biosciences reports Q3 results

Xenetic Biosciences Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken